EUCTR2010-022138-10-IT进行中（未招募）不适用
A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PERSISTENT IRRITATIVE URINARY SYMPTOMS - FI.LU.VA
AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI0 个研究点开始时间: 2011年6月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Age between 40 and 80 years • Men with LUTS and OAB defined by: – IPSS, flow assessment, measurement of post void residual urine – Mean urinary frequency ?8 times /24 hours.Mean number of urgency episodes, with or without urgency incontinence ?1 episode /24 hours. ? With both irritative and obstructive symptoms • Mean voided volume <400 ml as verified by the bladder diary completed prior to randomization • Qmax >5 ml/sec with a voided volume >150 ml • Evidence of a personally signed and dated informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Hypersensitivity to vardenafil or omnic • Drugs with proven or suspected incompatibility with vardenafil or omnic • Bladder failure or Neurogenic bladder • UTI / Prostatitis • LUT disease + LUT treatment • LUT surgery • Severe systemic disease • Unable to consistently and accurately complete the protocol
研究者
相似试验
已完成
不适用
A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER PILOT STUDY WITH TRAMADOL TO VALIDATE TWO EXPERIMENTAL HUMAN PAIN MODELS AT THE KENDLE CLINICAL PHARMACOLOGY UNITNeuropathic pain.10034606NL-OMON32672Kendle International12
已完成
不适用
A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMIC EFFECTS, SAFETY AND TOLERABILITY OF REPEATED DOSING OF RO5459072 IN HEALTHY SUBJECTSNL-OMON42481F. Hoffmann-La Roche Ltd.36
进行中（未招募）
不适用
A study to assess the effect of Aleglitazar on responsiveness (sensitivity) to insulin in patients with type 2 diabetesEUCTR2012-002649-39-DEF. Hoffmann-La Roche Ltd
未知
不适用
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PAHSE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF TKI258 COMBINED WITH FULVESTRANT, IN POSTMENOPAUSAL PATIENTS WITH HER-2 AND HR+ BREAST CANCER THAT HAVE EVIDENCE OF DISEASE PROGRESSION ON OR AFTER PRIOR ENDOCRINE THERAPYPER-072-12OVARTIS BIOSCIENSES PERU S.A.,
进行中（未招募）
不适用
Sleep efficiency assessed by Polysomnography (PSG sleep lab testing) in advanced Parkinson's diseaseAdvanced Parkinson's DiseaseMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-000056-42-GBCB Celltech, UK - Registered Branch of UCB Pharma SA